SCHEMBL2649469

SCHEMBL2649469

CC(C)c1nc(C(C)C)c(C(O)c2ccccc2)c(-c2ccc(F)cc2)c1CO

nearest known ligand 0.62

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 20/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2662970 1.00 GCGR (0.62) GCGR
SCHEMBL2662967 0.85 GCGR (0.76) GCGR
SCHEMBL2647298 0.83 GCGR (0.67) GCGR
SCHEMBL2649060 0.83 GCGR (0.71) GCGR
SCHEMBL2663055 0.82 GCGR (0.71) GCGR
SCHEMBL8949822 0.82 GCGR (0.88) GCGR
SCHEMBL2648267 0.82 GCGR (0.80) GCGR
SCHEMBL8876815 0.81 GCGR (0.61) GCGR
SCHEMBL2647636 0.80 GCGR (0.60) GCGR
SCHEMBL2647987 0.79 GCGR (0.69) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed